Alethia BioTherapeutics

Alethia BioTherapeutics is a clinical-stage biotechnology company in Montreal developing monoclonal-antibody therapeutics for cancer, including investigational sotevtamab (AB-16B5), which targets tumor-associated secreted clusterin. The company was established in 2002 and operates as Alethia Biotherapeutics ULC.